<span item_type="fundamental" item_id="180d63918c554c21fa4359d656727ccd" counter_id="ST/US/AFJK" env="prod"></span><span item_type="announcement" item_id="516112344431332865" env="prod"></span><p>EPS: As of FY2025 Q1, the actual value is USD 0.03.</p><p></p><h3>Segment Revenue</h3><ul><li>The company has not generated any operating revenue as of March 31, 2025, and will not generate any until after the completion of its initial business combination.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1979005/000164117225010315/form10-q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Net income for the three months ended March 31, 2025, was $184,662, compared to $755,500 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1979005/000164117225010315/form10-q.htm"></span></li><li>Formation and operating costs for the three months ended March 31, 2025, were - $413,414, compared to - $153,632 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1979005/000164117225010315/form10-q.htm"></span></li><li>Interest earned on assets held in trust for the three months ended March 31, 2025, was $598,076, compared to $909,132 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1979005/000164117225010315/form10-q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash used in operating activities for the three months ended March 31, 2025, was - $224,009, compared to - $166,970 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1979005/000164117225010315/form10-q.htm"></span></li><li>Net cash provided by investing activities for the three months ended March 31, 2025, was $30,787,800.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1979005/000164117225010315/form10-q.htm"></span></li><li>Net cash used in financing activities for the three months ended March 31, 2025, was - $30,584,654.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1979005/000164117225010315/form10-q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>Cash held in the Trust Account as of March 31, 2025, was $43,594,825, compared to $73,784,549 as of December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1979005/000164117225010315/form10-q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li>The company is focused on consummating a business combination by June 6, 2025, with United Hydrogen Group Inc., as per the definitive Business Combination Agreement entered on June 19, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1979005/000164117225010315/form10-q.htm"></span></li><li>The company has extended the timeframe for completing the business combination six times, with the latest extension until June 6, 2025, supported by monthly extension fees deposited into the Trust Account.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1979005/000164117225010315/form10-q.htm"></span></li><li>The company faces substantial doubt about its ability to continue as a going concern if it fails to consummate the business combination within the prescribed period.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1979005/000164117225010315/form10-q.htm"></span></li></ul>

Aimei Health Tech | 10-Q: FY2025 Q1 EPS: USD 0.03